Company intelligence / Profile preview

Refreshgene Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

Refreshgene has shown efficacy in restoring hearing in five out of six deaf children in a trial. Their lead product RRG001 for wet AMD is in Phase 1/2 trials in China, and RRG-003 for deafness is in Phase 1 trials. RRG-OTOF has received FDA Rare Pediatric Disease Designation and Orphan Drug Designation.

Therapeutic areas: CardiovascularMetabolic DisordersOphthalmologyOncologyNeurology
Modalities: AAV-based gene therapyDual Vector AAV
Industry: Biotech

Drug pipeline

2 assets

RRG001

1 more asset in the full pipeline.

Request access →

Partnerships

OBiO Technology Corp., Ltd.PackGene Biotech

Beyond the preview

Go deeper on Refreshgene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refreshgene Therapeutics.

Explore the full profile